VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
XERS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
HomeStocksXERSInstitutional Holders

XERS logoXeris Biopharma Holdings, Inc. (XERS) Institutional Ownership

Q2 2026 13F Data|Updated 2026-11-18

✨

Institutional ownership increased this quarter (+1.45 pp), though top 10 holders maintain a highly concentrated 50.2% of institutional value.

Institutional Ownership
Can exceed 100% due to securities lending, short interest, and reporting timing differences.
63.4%$859M total value · ▲ +1.45 pp vs prior quarter
Smart Money Score
Based on ownership concentration, fund quality, buying/selling activity, ownership indicators, and institutional trend.
60 / 100Bullish
Institutions & Flow239 holders+4 net flow (+29 / -25)

AI Insights & Key Takeaways

  • Positive Institutional Flow (+4)
  • Two Sigma Investments, Lp maintains a significant position
  • Top 10 holders control 50.2% of institutional value
  • No Insider Signal

Top Institutional Holders of XERS

Ranked by reported Q2 2026 13F market value

Top 10 Holders
50.2%
Top 25 Holders
72.8%

Share of total reported institutional value in XERS held by the largest 10 / 25 filers.

#InstitutionShares HeldMarket ValueQoQ ChangeOwnership %% of Fund
1BlackRock, Inc.14.5M$115.0M+12.2%8.414%0.00%
2D. E. Shaw & Co., Inc.7.8M$61.8M+0.2%4.521%0.03%
3VANGUARD CAPITAL MANAGEMENT LLC7.3M$58.1M+5.1%4.252%0.00%

Quarterly Institutional Activity

Filings activity in XERS during Q2 2026, grouped by how each filer changed its position.

OverviewNew Buyers29Added To175Trimmed26Exited25
  • Qube Research & Technologies Ltd$22.9M
  • Squarepoint Ops LLC$2.9M

XERS Institutional Ownership by Quarter

8 quarters of 13F filings · Δ columns show change vs prior quarter

QuarterInst. HoldersΔ HoldersOwnership %Δ OwnershipTotal 13F ValueΔ Value
Q2 2026239+2.6%63.39%+1.45 pp$859M+40%
Q1 2026233+3.6%61.94%+0.77 pp$613M21%
Q4 20252251.7%61.17%+2.13 pp$773M0.2%
Q3 2025229+14%59.04%+2.65 pp$774M+87%
Q2 2025201+2.0%56.39%+1.94 pp$414M9.3%
Q1 2025197+23%

How XERS Compares to Peers

Institutional ownership and quarterly buying activity across the largest Rare Disease Biotech peers.

TickerCompanyMarket CapInst. OwnershipHoldersNet Buyers − Sellers
IRLAIRulya Therapeutics Inc.$39M23.9%42-29

XERS — Frequently Asked Questions

Quick answers to the most common questions about buying XERS stock.

What percentage of XERS is owned by institutions?

Based on Q2 2026 13F filings, institutional ownership of Xeris Biopharma Holdings, Inc. stands at 63.4%, held across 239 reporting institutions.

Who is the largest institutional holder of XERS?

BlackRock, Inc. is the largest reported institutional holder of XERS, with approximately 14,525,539 shares worth $0.12B as of Q2 2026.

Is XERS a hedge fund favorite?

Yes — 1 widely-followed marquee investor appear among the top 25 institutional holders of XERS, including TWO SIGMA INVESTMENTS, LP.

What is XERS's Smart Money Score?

Our composite Smart Money Score for XERS is 60 out of 100 (Bullish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.

How many institutions bought XERS this quarter?
4STATE STREET CORP4.8M$38.2M+3.5%2.793%0.00%
5GEODE CAPITAL MANAGEMENT, LLC4.7M$37.4M+10.0%2.733%0.00%
6Nuveen, LLC4.4M$34.7M+50.3%2.540%0.01%
7Rosalind Advisors, Inc.2.9M$23.0M-10.0%1.685%8.56%
8Qube Research & Technologies Ltd2.9M$22.9M-29.7%1.676%0.02%
9VANGUARD PORTFOLIO MANAGEMENT LLC2.6M$20.8M-1.5%1.521%0.00%
10WELLINGTON MANAGEMENT GROUP LLP2.4M$18.7M+8.9%1.370%0.00%
11MORGAN STANLEY2.3M$18.5M-9.2%1.354%0.00%
12Legal & General Group Plc2.0M$15.9M+5.5%1.166%0.00%
13ARMISTICE CAPITAL, LLC2.0M$15.5M+2.6%1.134%0.19%
14TWO SIGMA INVESTMENTS, LP1.9M$14.9M-2.0%1.092%0.01%
15Parkman Healthcare Partners LLC1.8M$14.3M+5.0%1.047%1.47%
16ALGERT GLOBAL LLC1.7M$13.8M+50.6%1.010%0.16%
17NORTHERN TRUST CORP1.6M$12.7M+10.6%0.925%0.00%
18GOLDMAN SACHS GROUP INC1.6M$12.6M-1.2%0.923%0.00%
19AQR CAPITAL MANAGEMENT LLC1.5M$12.2M+10.5%0.893%0.00%
20CHARLES SCHWAB INVESTMENT MANAGEMENT INC1.5M$11.8M+9.8%0.864%0.00%
21FEDERATED HERMES, INC.1.4M$11.4M+67.4%0.831%0.02%
22BANK OF AMERICA CORP /DE/1.4M$11.1M+59.8%0.809%0.00%
23UBS Group AG1.3M$10.3M-21.0%0.754%0.00%
24Ishara Investments LP1.2M$9.7M+20.0%0.713%7.16%
25VANGUARD FIDUCIARY TRUST CO1.2M$9.7M+8.0%0.709%0.00%

denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in XERS — a direct measure of their conviction.

SEI INVESTMENTS CO
$2.7M
  • Trexquant Investment LP$2.7M
  • CenterBook Partners LP$2.2M
  • HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND$2.1M
  • CANADA PENSION PLAN INVESTMENT BOARD$1.7M
  • MILLENNIUM MANAGEMENT LLC$1.0M
  • Connor, Clark & Lunn Investment Management Ltd.$1.0M
  • ALLIANCEBERNSTEIN L.P.$843K
  • JANE STREET GROUP, LLC$590K
  • RENAISSANCE TECHNOLOGIES LLC$533K
  • 54.45%
    +11.02 pp
    $456M
    +113%
    Q4 2024160+13%43.43%+0.33 pp$214M+22%
    Q3 2024142—43.10%—$175M—

    Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.

    29 institutions opened new positions in XERS during Q2 2026, while 25 fully exited. 175 added to existing positions and 26 trimmed.

    How is institutional ownership of XERS changing?

    XERS institutional ownership rose by 1.45 percentage points quarter-over-quarter, with a net change of +6 holders.

    How concentrated is XERS ownership among the top holders?

    The top 10 institutions account for 50.2% of all reported 13F value in XERS, and the top 25 account for 72.8%.

    How does XERS compare to Rare Disease Biotech on institutional ownership?

    Across the largest Rare Disease Biotech peers, institutional ownership levels are: IRLA (23.9%). See the peer comparison table on this page for net buyer activity by company.

    Where does this XERS institutional ownership data come from?

    All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.

    XERSXeris Biopharma Holdings, Inc.
    $16.99$2.9B
    Overview & Tools
    OverviewChart Terminal ↗Visualize
    Valuation & Forecasts
    Valuation ModelsEstimatesDCF Model
    Price & Analyst Data
    Analyst TargetsPrice History
    Financial Statements
    Income StatementBalance SheetCash FlowRatios & Margins
    Performance
    P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
    Discovery & Screens
    Live BreakoutsStock ScreenerOwnership